Literature DB >> 16322789

New ways in which GLP-1 can regulate glucose homeostasis.

David A D'Alessio1, Darleen A Sandoval, Randy J Seeley.   

Abstract

Glucagon-like peptide-1 (GLP-1) has a diverse set of peripheral actions which all serve to promote enhanced glucose tolerance, and for this reason it has become the basis for new treatments for type 2 diabetes. In this issue of the JCI, Knauf et al. provide clear evidence that GLP-1 signaling in the CNS is also linked to the control of peripheral glucose homeostasis by inhibiting non-insulin-mediated glucose uptake by muscle and increasing insulin secretion from the pancreas. The authors' work points to an important need to integrate diverse GLP-1 signaling actions and peripheral GLP-1 function in order to better understand both normal and abnormal glucose homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322789      PMCID: PMC1297270          DOI: 10.1172/JCI27207

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride.

Authors:  R J Seeley; K Blake; P A Rushing; S Benoit; J Eng; S C Woods; D D'Alessio
Journal:  J Neurosci       Date:  2000-02-15       Impact factor: 6.167

2.  Portal glucose infusion exerts an incretin effect associated with changes in pancreatic neural activity in conscious dogs.

Authors:  Beth E Dunning; Mary Courtney Moore; Tadasu Ikeda; Doss W Neal; Melanie F Scott; Alan D Cherrington
Journal:  Metabolism       Date:  2002-10       Impact factor: 8.694

3.  The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness.

Authors:  Kimberly P Kinzig; David A D'Alessio; Randy J Seeley
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

4.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

Authors:  Mette Zander; Sten Madsbad; Jan Lysgaard Madsen; Jens Juul Holst
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

5.  Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal.

Authors:  Catherine A Dicostanzo; Dominique P Dardevet; Doss W Neal; Margaret Lautz; Eric Allen; Wanda Snead; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-08-16       Impact factor: 4.310

6.  Glucose disposal is not proportional to plasma glucose level in man.

Authors:  J D Best; G J Taborsky; J B Halter; D Porte
Journal:  Diabetes       Date:  1981-10       Impact factor: 9.461

7.  CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors.

Authors:  Kimberly P Kinzig; David A D'Alessio; James P Herman; Randall R Sakai; Torsten P Vahl; Helmer F Figueiredo; Erin K Murphy; Randy J Seeley; Helmer F Figueredo
Journal:  J Neurosci       Date:  2003-07-16       Impact factor: 6.167

8.  Intraportal glucose infusion matched to oral glucose absorption. Lack of evidence for "gut factor" involvement in hepatic glucose storage.

Authors:  R N Bergman; J R Beir; P M Hourigan
Journal:  Diabetes       Date:  1982-01       Impact factor: 9.461

9.  Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

Authors:  Hiroshi Yamamoto; Charlotte E Lee; Jacob N Marcus; Todd D Williams; J Michael Overton; Marisol E Lopez; Anthony N Hollenberg; Laurie Baggio; Clifford B Saper; Daniel J Drucker; Joel K Elmquist
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

10.  Glucagon-like peptide-1 7-36: a physiological incretin in man.

Authors:  B Kreymann; G Williams; M A Ghatei; S R Bloom
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

View more
  17 in total

Review 1.  Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery.

Authors:  David E Cummings; Joost Overduin; Karen E Foster-Schubert; Molly J Carlson
Journal:  Surg Obes Relat Dis       Date:  2007 Mar-Apr       Impact factor: 4.734

2.  Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors.

Authors:  Jixin Zhong; Andrei Maiseyeu; Sanjay Rajagopalan
Journal:  Clin Lipidol       Date:  2015

Review 3.  A Plethora of GLP-1 Agonists: Decisions About What to Use and When.

Authors:  Susan L Samson; Alan J Garber
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

Review 4.  Central nervous system control of metabolism.

Authors:  Martin G Myers; David P Olson
Journal:  Nature       Date:  2012-11-15       Impact factor: 49.962

5.  The changes of pro-opiomelanocortin neurons in type 2 diabetes mellitus rats after ileal transposition: the role of POMC neurons.

Authors:  Weijie Chen; Zhibo Yan; Shaozhuang Liu; Guangyong Zhang; Dong Sun; Sanyuan Hu
Journal:  J Gastrointest Surg       Date:  2011-06-30       Impact factor: 3.452

6.  Metabolic manifestations of insulin deficiency do not occur without glucagon action.

Authors:  Young Lee; Eric D Berglund; May-yun Wang; Xiaorong Fu; Xinxin Yu; Maureen J Charron; Shawn C Burgess; Roger H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-13       Impact factor: 11.205

7.  Acute and repeated restraint differentially activate orexigenic pathways in the rat hypothalamus.

Authors:  Samantha L Chagra; Jaidee K Zavala; Mara V Hall; Kristin L Gosselink
Journal:  Regul Pept       Date:  2010-12-03

Review 8.  Regulation of glucose homeostasis by GLP-1.

Authors:  Prashant Nadkarni; Oleg G Chepurny; George G Holz
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

9.  Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain.

Authors:  Michael Gejl; Susanne Lerche; Lærke Egefjord; Birgitte Brock; Niels Møller; Kim Vang; Anders B Rodell; Bo M Bibby; Jens J Holst; Jørgen Rungby; Albert Gjedde
Journal:  Front Neuroenergetics       Date:  2013-03-27

10.  Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Tetsuharu Oriishi; Michio Sata
Journal:  Case Rep Gastroenterol       Date:  2012-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.